- |||||||||| dexamethasone / Generic mfg.
Cardiometabolic Risk and Outcomes in Patient with Adrenal Adenomas (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_531;
Patients with adrenal adenomas and mild autonomous cortisol secretion (MACS) are at increased risk of cardiovascular events requiring intervention and cerebrovascular events, compared to non-functioning adrenal tumors. 41% (n=82, 61% Blacks, 30% White, 2% Others) of patient populationwas classified as unknown cortisol status indicating further need to educate health care professionals on evaluation of adrenal adenomas to improve health care outcomes and disparities in management.
- |||||||||| dexamethasone / Generic mfg.
Prevalence of Vertebral Fractures in Patients with Adrenal Adenomas (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_529;
Black patients with adrenal adenomas and vertebral fractures have lower BMD compared to White patients. 41% (n=82, 61% AA, 30% Caucasians, 2% Other) of patients were classified as unknown cortisol status indicating further need to educate health care professionals on evaluation of adrenal adenomas to improve health care outcomes and disparities in management.
- |||||||||| dexamethasone / Generic mfg.
Investigation of cut off values for identifying cortisol excess in adrenal venous blood sampling (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_522;
5 mg/dL after a 1 mg dexamethasone suppression test (DST) and underwent segmental AVS (sAVS) at our hospital from 2009-2020 (n = 75).Patients who underwent AVS on only one side had an adrenocorticotropic hormone (ACTH) level of > 10 pg/mL after 1 mg DST, a midnight Cort level of < 5.0 mg/dL, bilateral cortisol-producing tumors, and/or adrenal cancer, were excluded (n = 26).The control group with normal Cort secretion included patients with Cort level of < 1.8 mg/dL after 1 mg DST who underwent sAVS and whose resected adrenal tumor was negative or weakly positive in 11?-hydroxylase cytochrome P450 staining (n = 45)... Novel cutoff values were proposed to identify excess cortisol in AVS.
- |||||||||| dexamethasone / Generic mfg.
Can 11-Dehydrodexamethasone Improve The Salivary Dexamethasone Suppression Test? (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_520;
It is hypothesised that the non-linear correlation might be due to saturation kinetics of the enzyme 11?-HSD2 in the salivary duct, a similar relationship was observed when comparison of salivary cortisol and cortisone was assessed. The development of this LC-MS/MS assay for salivary measurement of 11-dehydrodexamethasone opens the possibility for a fully remote DST, whereby patients could administer the drug and take a 9am saliva sample.
- |||||||||| BIUXX (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_513;
Use of Spironolactone unmasked natriuresis by blocking aldosterone activity on the intercalated cells of the renal nephron. Stopping Oxcarbazepine ultimately resulted in hyponatremia resolution.
- |||||||||| Worsening Shortness of Breath After a Mild Case of Covid-19 (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_502;
This patient will require repeated imaging and follow up. The long-term consequences of this finding are unknown and this patient has a history of night sweats which preceded the COVID course.
- |||||||||| Metopirone (metyrapone) / HRA Pharma
Ectopic Cushing Syndrome in a case of Ewing Sarcoma (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_274;
The severity of hypercortisolism is a negative predictor of survival and prompt control should be the main therapeutic goal along with prevention of cortisol-induced complications in patients with ECS. ACTH and CRH immunostaining of the patient's ES histopathology slides is pending.
- |||||||||| dexamethasone / Generic mfg.
Aggressive Cushing's: A Rare Case of Pancreatic ACTHoma in a Young Female (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_273;
ACTHoma is a very rare disease that causes hypercortisolemia. Reporting of similar cases will provide insight into its clinical features, immunohistochemical characteristics, diagnosis, therapy, and prognosis.
- |||||||||| Metopirone (metyrapone) / HRA Pharma, Mifeprex (mifepristone) / Danco Laboratories
An Unusual case of Ectopic ACTH Syndrome Secondary to Non-Small Cell Lung Cancer (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_259;
However, our case is novel as the sourceof ACTH was a lung tumor of squamous cell origin. Treatment strategies for ACTH secreting tumors combine chemotherapy as well as medications that target the hormonal imbalance such as steroidogenesis inhibitors and cortisol receptor blockers.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
A Case of Severe Type B Insulin Resistance Successfully Treated With Combined Immunosuppressive Therapy (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_201;
Review of her continuous glucose monitor showed no episodes of hypoglycemia.ConclusionThis rare case demonstrates the successful treatment of type B insulin resistance using metformin, pioglitazone, and combination immunosuppressive therapy with rituximab, cyclophosphamide, and pulse-dose steroids, followed by maintenance azathioprine. With a mortality rate over 50%, the use of combined immunosuppressive therapy has transformed this condition into a curable form of diabetes and should be recommended in all patients with type B insulin resistance.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Late Onset of Immune Checkpoint Inhibitor-related Diabetes after 3 years (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_181;
He had recent evidence of progression, so chemotherapy adjustment was planned, and he started dexamethasone 4mg on the day prior to presentation...He continued to have hyperglycaemia while on NPH /Novolog regimen, thus he was switched to Lantus and Novolog regimen with better glycaemic control... Although the mean interval between the first ICI administration and T1DM development was found to be 201
- |||||||||| hydrocortisone / Generic mfg.
Fitting together the pieces of the puzzle between isolated ACTH deficiency and immunodeficiency: DAVID syndrome (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_123;
This patient is unique in having asymptomatic, acquired, isolated ACTH deficiency diagnosed in later childhood, despite having frequent sinopulmonary infections since infancy as part of DAVID syndrome. Further research needs to be done to elucidate how NFKB2 variants contribute to acquired, isolated, central ACTH deficiency or autoimmune pituitary disease.
- |||||||||| hydrocortisone / Generic mfg.
Review, Journal, IO biomarker: Advancements in the pharmacological management of sepsis in the elderly. (Pubmed Central) - May 11, 2023
Antibioticshave been the cornerstone for the treatment of sepsis while immune modulatorytherapies, except hydrocortisone, have gained a lot of attention lately...Adjunctive precision immunotherapy treatment is a new era of research which recentlyattracts much attention. Combination of antibiotics with precisionimmunotherapy inan individualized pattern may be the key for decreasing mortality and improveoutcomes.
- |||||||||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: SeluDex: International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia (clinicaltrials.gov) - May 11, 2023
P1/2, N=12, Terminated,
Systemic dexamethasone resulted in a similar duration as placebo. N=42 --> 12 | Trial completion date: Dec 2023 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> May 2023; Poor recruitment, due to a change in the standard of care for this patient population with the use of CAR-T cells
- |||||||||| Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
Enrollment open, Combination therapy: ARCHED: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 11, 2023
P3, N=330, Recruiting,
N=42 --> 12 | Trial completion date: Dec 2023 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> May 2023; Poor recruitment, due to a change in the standard of care for this patient population with the use of CAR-T cells Not yet recruiting --> Recruiting
- |||||||||| dexamethasone / Generic mfg.
Journal: Comments on the systemic corticosteroid strategy for the coronavirus disease 2019 (COVID-19) (Pubmed Central) - May 10, 2023
However, based on the outcomes of variable clinical trials and our clinical experience in treating the COVID-19 patients, the starting time, initial dosage and course of corticosteroid might be varied case by case. Individualized administration of corticosteroid is suggested according to the COVID-19 patient's demographic characteristics, underlying disease and immune status, severity and progression rate of COVID-19, inflammatory condition and concomitant use of non-steroidal anti-inflammatory drugs.
- |||||||||| dexamethasone / Generic mfg., doxercalciferol / Generic mfg.
Journal, Machine learning: Interactome-Based Machine Learning Predicts Potential Therapeutics for COVID-19. (Pubmed Central) - May 10, 2023
Such predictions are carried out by random forest as it is found to perform better than other predictors, providing an accuracy of 90.53% for human-spike PPI and 96.15% for drug-protein interactions. Finally, 40 unique drugs like eicosapentaenoic acid, doxercalciferol, ciclesonide, dexamethasone, methylprednisolone, etc. are identified that target 32 human proteins like ACACA, DST, DYNC1H1, etc.
- |||||||||| Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca
Trial completion date, Trial primary completion date, Real-world evidence, Patient reported outcomes, Real-world: RECORD: REported Outcomes in COPD With Trixeo in Real worlD in Germany (clinicaltrials.gov) - May 10, 2023
P=N/A, N=500, Recruiting,
Finally, 40 unique drugs like eicosapentaenoic acid, doxercalciferol, ciclesonide, dexamethasone, methylprednisolone, etc. are identified that target 32 human proteins like ACACA, DST, DYNC1H1, etc. Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
- |||||||||| hydrocortisone / Generic mfg.
Trial completion date, Trial primary completion date: CORVICTES: Vitamin C, Hydrocortisone and Thiamine for Septic Shock (clinicaltrials.gov) - May 10, 2023
P2, N=400, Recruiting,
Trial completion date: Dec 2022 --> May 2025 | Trial primary completion date: Dec 2022 --> May 2025 Trial completion date: Oct 2022 --> Dec 2025 | Trial primary completion date: Jul 2022 --> Dec 2025
- |||||||||| hydrocortisone / Generic mfg., epinephrine / Generic mfg.
Trial completion date, Trial primary completion date: Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest. (clinicaltrials.gov) - May 10, 2023
P=N/A, N=191, Not yet recruiting,
Trial completion date: Oct 2022 --> Dec 2025 | Trial primary completion date: Jul 2022 --> Dec 2025 Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Trial completion date, FDG PET, Metastases: CRUK-07/146: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma (clinicaltrials.gov) - May 10, 2023
P3, N=1202, Active, not recruiting,
Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2025 Trial completion date: Jan 2022 --> May 2023
- |||||||||| dexamethasone / Generic mfg., epinephrine / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Comparing Local Anesthesia With and Without iPACK Block (clinicaltrials.gov) - May 10, 2023
P4, N=120, Recruiting,
N=396 --> 662 | Trial completion date: Nov 2024 --> Mar 2029 | Trial primary completion date: Apr 2023 --> Mar 2029 Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
- |||||||||| dexamethasone / Generic mfg.
Journal: Influence of corticosteroid treatment on CXCR4 expression in DLBCL. (Pubmed Central) - May 10, 2023
This confirms that at least the corticosteroid component of stabilizing chemotherapy regimens in DLBCL patients prior to [Lu]Lu-PentixaTher RLT does not lead to downregulation of the molecular target CXCR4 and may even have a beneficiary effect. However, further studies are needed to investigate if and to what extent the other commonly used chemotherapeutic agents affect CXCR4 expression on DLBCL to ensure the choice of an appropriate treatment regimen prior to [Lu]Lu/[Y]Y-PentixaTher RLT.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Catastrophic ACTH-secreting pheochromocytoma: an uncommon and challenging entity with multifaceted presentation. (Pubmed Central) - May 10, 2023
The combination of antihypertensive drugs, high-dose potassium infusion, insulin and steroidogenesis inhibitor normalized BP, metabolic parameters and cortisol levels; laparoscopic left adrenalectomy under intravenous hydrocortisone infusion was performed...Immediate-acting steroidogenesis inhibitors are required for the treatment of hypercortisolism, and catecholamine excess should also be appropriately managed before surgical removal of the tumour. A multidisciplinary approach is required for the treatment of this challenging entity.
- |||||||||| vamorolone (VBP15) / Santhera
Undergraduate research-based education for identifying new treatment options for cystic fibrosis (Poster Area) - May 9, 2023 - Abstract #ECFS2023ECFS_475;
The students investigated the effects of VBP15 on intra- and extracellular MUC5AC and MUC5B expression, cell morphology, and toxicity. This research-based educational concept enhances student learning and development of skills that future professionals need to tackle complex problems with creative thinking and interdisciplinary collaboration, and with this concept innovative research for CF can be initiated potentially leading to better treatment options for all CF patients.
- |||||||||| triamcinolone acetonide / Generic mfg., 5-fluorouracil / Generic mfg., ropivacaine / Generic mfg.
Journal: Sufficient mesh polyhedral intralesional injection for treatment of keloids. (Pubmed Central) - May 9, 2023
In the majority of cases the rash was self-limiting without drug discontinuation and only one patient required up-titration of the dose. The sufficient mesh polyhedral intralesional injection can achieve excellent results for the treatment of keloid scars.
|
